Solid Biosciences Inc. Gain (Loss) on Termination of Lease
Solid Biosciences Inc. (SLDB) reported Gain (Loss) on Termination of Lease of $89.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2024-05-15
- Solid Biosciences Inc. gain (loss) on termination of lease for the quarter ending 2024-03-31 was $89.00K.
- Solid Biosciences Inc. gain (loss) on termination of lease for fiscal 2022 was $249.00K, a 207.41% increase from fiscal 2021.
- Solid Biosciences Inc. gain (loss) on termination of lease for fiscal 2021 was $81.00K.
| Period end | Gain (Loss) on Termination of Lease 3 month | Gain (Loss) on Termination of Lease 6 month | Gain (Loss) on Termination of Lease 9 month | Gain (Loss) on Termination of Lease 12 month |
|---|---|---|---|---|
| 2024-03-31 | $89.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $249.00K 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $249.00K 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $249.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $81.00K 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |